High D-dimer plasma concentration in systemic sclerosis patients: Prevalence and association with vascular complications

Furtado, Sofia; Dunogué, Bertrand; Jourdi, Georges; Chaigne, Benjamin; Chibah, Aziza; Legendre, Paul; Mouthon, Luc

doi:10.1177/2397198320957558

Cited by 9 publications

(5 citation statements)

References 34 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Remarkably, this participant had no signs and symptoms of thrombotic diseases. There were numerous potential factors influencing the elevation in D-dimer values such as transient infection or inflammation, injuries, hypertension [ 26 ], or systemic sclerosis [ 27 ]. Elevated D-dimer levels could also be observed in healthy people, especially in members of the elderly population [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

Longitudinal Profiles of Anti-Platelet Factor 4 Antibodies in Thai People Who Received ChAdOx1 nCoV-19 Vaccination

et al. 2023

View full text Add to dashboard Cite

Anti-platelet factor 4 (anti-PF4) antibodies were identified as pathogenic antibodies for vaccine-induced immune thrombocytopenia and thrombosis (VITT) in subjects receiving ChAdOx1 nCoV-19 vaccinations. We performed a prospective cohort study to determine the prevalence of anti-PF4 and the effect of the ChAdOx1 nCoV-19 vaccine on anti-PF4 in healthy Thai subjects. Anti-PF4 antibodies were measured before and four weeks after receiving the first vaccination. Participants with detectable antibodies were scheduled for repeat anti-PF4 analysis at 12 weeks after the second vaccination. Of 396 participants, ten participants (2.53%; 95% confidence interval [CI], 1.22–4.59) were positive for anti-PF4 before receiving vaccinations. Twelve people (3.03%; 95% CI, 1.58–5.23) had detectable anti-PF4 after the first vaccination. There was no difference in the optical density (OD) values of anti-PF4 antibodies when comparisons were made between pre-vaccination and four weeks after the first vaccination (p = 0.0779). There was also no significant difference in OD values in participants with detectable antibodies. No subjects experienced thrombotic complications. Pain at the injection site was associated with an increased risk of being anti-PF4 positive at an odds ratio of 3.44 (95% CI, 1.06–11.18). To conclude, the prevalence of anti-PF4 was low in Thais and did not significantly change over time.

show abstract

Section: Discussionmentioning

confidence: 99%

Longitudinal Profiles of Anti-Platelet Factor 4 Antibodies in Thai People Who Received ChAdOx1 nCoV-19 Vaccination

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In chordoma patients, a preoperative measurement above the cut-off values of 12.7 for RDW (in a spine chordoma population) and 840 mg/L for D-dimer (in a skull base chordoma population) were associated with a poor prognosis. However, these biomarkers do not provide an insight about the underlying disease mechanism, and they lack specificity (106)(107)(108).…”

Section: Discussionmentioning

confidence: 99%

“…The last two biomarkers were assessed in blood samples and are the most promising in terms of affordability, limited invasiveness, reproducibility, assay technique, and required sample size ( 22 , 46 ). Other studies have reported that increased levels of RDW or D-dimer are observed in many types of cancers and act as useful markers of adverse prognosis ( 103 – 106 ). In chordoma patients, a preoperative measurement above the cut-off values of 12.7 for RDW (in a spine chordoma population) and 840 μg/L for D-dimer (in a skull base chordoma population) were associated with a poor prognosis.…”

Section: Discussionmentioning

confidence: 99%

Prognostic molecular biomarkers in chordomas: A systematic review and identification of clinically usable biomarker panels

Rubino

Alvarez‐Breckenridge²,

Akdemir³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Introduction and objectiveDespite the improvements in management and treatment of chordomas over time, the risk of disease recurrence remains high. Consequently, there is a push to develop effective systemic therapeutics for newly diagnosed and recurrent disease. In order to tailor treatment for individual chordoma patients and develop effective surveillance strategies, suitable clinical biomarkers need to be identified. The objective of this study was to systematically review all prognostic biomarkers for chordomas reported to date in order to classify them according to localization, study design and statistical analysis.MethodsUsing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we systematically reviewed published studies reporting biomarkers that correlated with clinical outcomes. We included time-to-event studies that evaluated biomarkers in skull base or spine chordomas. To be included in our review, the study must have analyzed the outcomes with univariate and/or multivariate methods (log-rank test or a Cox-regression model).ResultsWe included 68 studies, of which only 5 were prospective studies. Overall, 103 biomarkers were analyzed in 3183 patients. According to FDA classification, 85 were molecular biomarkers (82.5%) mainly located in nucleus and cytoplasm (48% and 27%, respectively). Thirty-four studies analyzed biomarkers with Cox-regression model. Within these studies, 32 biomarkers (31%) and 22 biomarkers (21%) were independent prognostic factors for PFS and OS, respectively.ConclusionOur analysis identified a list of 13 biomarkers correlating with tumor control rates and survival. The future point will be gathering all these results to guide the clinical validation for a chordoma biomarker panel. Our identified biomarkers have strengths and weaknesses according to FDA’s guidelines, some are affordable, have a low-invasive collection method and can be easily measured in any health care setting (RDW and D-dimer), but others molecular biomarkers need specialized assay techniques (microRNAs, PD-1 pathway markers, CDKs and somatic chromosome deletions were more chordoma-specific). A focused list of biomarkers that correlate with local recurrence, metastatic spread and survival might be a cornerstone to determine the need of adjuvant therapies.

show abstract

“…Compared to the general population, patients with SSc have a 10.5-fold increased risk of DVT and a 7-fold increased risk of PTE [ 95 ], especially within the first year after SSc diagnosis [ 96 ]. This may be related to the persistent chronic inflammation present in SSc patients leading to arterial and microvascular thrombosis [ 18 ], a conclusion supported by the elevated levels of D-dimer found by FURTADO et al in SSc patients [ 97 ]. Higher levels of VWF, VWFpp, and lower levels of ADAMTS-13 in the plasma of patients with SSc indicate the hypercoagulable state that characterizes SSc [ 23 ].…”

Section: Vte Associated With Ctd-ildmentioning

confidence: 99%

Under the dual effect of inflammation and pulmonary fibrosis, CTD-ILD patients possess a greater susceptibility to VTE

Jiang,

Jia,

Dong

2024

Thrombosis J

View full text Add to dashboard Cite

As an autoimmune disease, the persistent systemic inflammatory response associated with connective tissue disease (CTD) is involved in the development of venous thromboembolism (VTE). However, clinical data showed that the risk of VTE in patients differed between subtypes of CTD, suggesting that different subtypes may have independent mechanisms to promote the development of VTE, but the specific mechanism lacks sufficient research at present. The development of pulmonary fibrosis also contributes to the development of VTE, and therefore, patients with CTD-associated interstitial lung disease (CTD-ILD) may be at higher risk of VTE than patients with CTD alone or patients with ILD alone. In addition, the activation of the coagulation cascade response will drive further progression of the patient’s pre-existing pulmonary fibrosis, which will continue to increase the patient’s risk of VTE and adversely affect prognosis. Currently, the treatment for CTD-ILD is mainly immunosuppressive and antirheumatic therapy, such as the use of glucocorticoids and janus kinase-inhibitors (JAKis), but, paradoxically, these drugs are also involved in the formation of patients’ coagulation tendency, making the clinical treatment of CTD-ILD patients with a higher risk of developing VTE challenging. In this article, we review the potential risk factors and related mechanisms for the development of VTE in CTD-ILD patients to provide a reference for clinical treatment and prevention.

show abstract

High D-dimer plasma concentration in systemic sclerosis patients: Prevalence and association with vascular complications

Cited by 9 publications

References 34 publications

Longitudinal Profiles of Anti-Platelet Factor 4 Antibodies in Thai People Who Received ChAdOx1 nCoV-19 Vaccination

Longitudinal Profiles of Anti-Platelet Factor 4 Antibodies in Thai People Who Received ChAdOx1 nCoV-19 Vaccination

Prognostic molecular biomarkers in chordomas: A systematic review and identification of clinically usable biomarker panels

Under the dual effect of inflammation and pulmonary fibrosis, CTD-ILD patients possess a greater susceptibility to VTE

Contact Info

Product

Resources

About